[{"indications": "Indications\u00a0treatment of oestrogen-receptor-positive metastatic or locally advanced\r\nbreast cancer in postmenopausal women in whom disease progresses or\r\nrelapses while on, or after, other anti-oestrogen therapy", "name": "FULVESTRANT", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.1 Breast cancer", "FULVESTRANT"], "side-effects": "Side-effects\u00a0nausea, vomiting, diarrhoea; venous thromboembolism;\r\nanorexia, headache, asthenia; urinary-tract infections; hot flushes;\r\nback pain; rash, injection-site reactions, hypersensitivity reactions; less commonly vaginal haemorrhage, vaginal candidiasis,\r\nand leucorrhoea", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128317.htm", "doses": ["By deep intramuscular injection into buttock,\r\n500\u00a0mg every 2 weeks for the first 3 doses, then 500\u00a0mg every month", "500\u00a0mg dose should be administered as one\r\n250-mg injection (slowly over 1\u20132 minutes) into each buttock"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid\u2014increased incidence of\r\nfetal abnormalities and death in animal studies "}]